Century Therapeutics (NASDAQ:IPSC) Trading Down 0.8%

Century Therapeutics, Inc. (NASDAQ:IPSC)’s stock price traded down 0.8% during trading on Monday . The company traded as low as $1.28 and last traded at $1.28. 122,879 shares were traded during mid-day trading, a decline of 11% from the average session volume of 137,408 shares. The stock had previously closed at $1.29.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. HC Wainwright reduced their target price on Century Therapeutics from $17.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, August 10th. Piper Sandler reduced their target price on Century Therapeutics from $14.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, August 10th. Chardan Capital cut their price objective on Century Therapeutics from $19.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, August 9th. Finally, JPMorgan Chase & Co. downgraded Century Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $28.00 to $5.00 in a report on Monday, August 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.57.

Century Therapeutics Stock Performance

The stock has a market capitalization of $76.58 million, a price-to-earnings ratio of -0.58 and a beta of 0.75. The company has a 50 day moving average of $1.82 and a 200 day moving average of $2.62.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its stake in Century Therapeutics by 27.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,157 shares of the company’s stock worth $41,000 after purchasing an additional 904 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Century Therapeutics by 11.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 20,746 shares of the company’s stock worth $261,000 after acquiring an additional 2,091 shares in the last quarter. American International Group Inc. boosted its position in shares of Century Therapeutics by 37.1% during the 1st quarter. American International Group Inc. now owns 8,604 shares of the company’s stock worth $108,000 after acquiring an additional 2,328 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Century Therapeutics by 3.7% during the 4th quarter. JPMorgan Chase & Co. now owns 65,461 shares of the company’s stock worth $335,000 after acquiring an additional 2,360 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Century Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 153,323 shares of the company’s stock worth $787,000 after acquiring an additional 2,976 shares in the last quarter. 32.28% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.